Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × MK 2206 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 12 Neoplasms 5 Ovarian Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Rectal Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Gallbladder Neoplasms 2 Fallopian Tube Neoplasms 2 Colonic Neoplasms 2 Breast Neoplasms, Male 2 Waldenstrom Macroglobulinemia 1 Thymoma 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Salivary Gland Neoplasms 1 Recurrent Squamous Cell Carcinoma of the Nasopharynx 1 Recurrence 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Nasopharyngeal Carcinoma 1 Myeloproliferative Syndrome, Transient 1

Interventions

Temozolomide 140 Bevacizumab 63 Radiotherapy 54 Magnetic Resonance Spectroscopy 52 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 18 Radiation 18 Carmustine 18 Specimen Handling 17 Nivolumab 16 Lomustine 15 Biopsy 15 Aminolevulinic Acid 15 pembrolizumab 12 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 9 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 X-Rays 8 Imatinib Mesylate 8 Filgrastim 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01249105 2016-03-10

MK-2206 for Recurrent Malignant Glioma

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡